Overview
Enhancing Survival and Minimizing Toxicity: Leveraging New Research in HER2+ and HR+/HER2- Breast Cancers
Personalized Learning Platform powered by CustomED®
Click the "Start Activity" button to indicate you have reviewed the CME/CE information for this activity.
Start ActivityCME/CE is no longer available for this activity
This robust, online content repository powered by CustomED™ offers a comprehensive review of early and metastatic HER2+ and HR+/HER- breast cancers to help clinicians better interpret emerging data and improve knowledge. Customize your own slide deck by tumor type or get more specific content related to the following topics: toxicities in early breast cancer, selection of therapy, novel agents’ mechanism of action, disease management, and emerging therapies
This activity is targeted to physicians in oncology, obstetrics and gynecology, pathology, radiology and surgery.
• Clinicians will be informed of targeted therapies/treatments available for breast cancer (HER2+ and HR+/HER2) leading to enhanced confidence in the early stage of breast cancer
• Enhanced knowledge of selecting optimal therapeutic treatment regimens for metastatic breast cancer
• Acquired knowledge on evaluating newly approved agents and recognizing availability of agents in the breast cancer pipeline as well as enhanced understanding on appropriate referral and selection of patients into clinical trials
• Enhanced knowledge of selecting optimal therapeutic treatment regimens for metastatic breast cancer
• Acquired knowledge on evaluating newly approved agents and recognizing availability of agents in the breast cancer pipeline as well as enhanced understanding on appropriate referral and selection of patients into clinical trials
At the conclusion of this educational activity, the participant should be able to:
• Describe new strategies being employed or under investigation to minimize toxicities in early breast cancer
• Explain how novel drug classes, either recently approved or nearing FDA approval, are influencing the treatment of metastatic breast cancer
• Discuss the mechanisms of action and key features of novel agents for breast cancer with recent FDA approval or nearing FDA approva
• Describe new strategies being employed or under investigation to minimize toxicities in early breast cancer
• Explain how novel drug classes, either recently approved or nearing FDA approval, are influencing the treatment of metastatic breast cancer
• Discuss the mechanisms of action and key features of novel agents for breast cancer with recent FDA approval or nearing FDA approva
Supported by educational grants from AstraZeneca and Daiichi Sankyo.
Naoto T. Uneo, MD, PhD, FACP (Chairperson)
Professor of Medicine
Section Chief, Translational Brest Cancer Research
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Professor of Medicine
Section Chief, Translational Brest Cancer Research
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Virginia Kaklamani, MD, DSc
Professor of Medicine
Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment
A.B. Alexander Distinguished Chair in Oncology
Associate Director for Clinical Research
Leader, Breast Oncology Program
UT Health San Antonio, MD Anderson Cancer Center
